Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

NCT06158841 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06158841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06158841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 19, 2024
Completion date
December 31, 2027
Enrollment
421 (actual)
Sites
166

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma